Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VTYX Stock Price Chart Interactive Chart >
VTYX Price/Volume Stats
| Current price | $34.91 | 52-week high | $41.29 |
| Prev. close | $35.12 | 52-week low | $9.50 |
| Day low | $34.42 | Volume | 840,779 |
| Day high | $37.28 | Avg. volume | 304,736 |
| 50-day MA | $24.22 | Dividend yield | N/A |
| 200-day MA | $16.86 | Market Cap | 1.78B |
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Latest VTYX News From Around the Web
Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.
Ventyx Biosciences (VTYX) Gets a Buy from H.C. WainwrightH.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Ventyx Biosciences (VTYX - Research Report) today and set a price target of $50.00. The company's shares opened today at $35.61.According to TipRanks, Bodnar is an analyst with an average return of -18.6% and a 20.59% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Imunon, Context Therapeutics, and Ventyx Biosciences.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ventyx Biosciences with a $53.71 average price target, which is a 50.83% upside from current levels. |
10 Best-Performing Non-Energy Stocks of 2022In this article, we discuss 10 best performing non-energy stocks of 2022. If you want to see more stocks in this selection, click 5 Best-Performing Non-Energy Stocks of 2022. On Friday, September 16, Wall Street concluded another one of its abysmal weeks in months, as investors reacted to a weak earnings indication from FedEx regarding […] |
Ventyx Biosciences Announces $176.6 Million Private Placement of Common StockENCINITAS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 5,350,000 shares of its common stock at an offering price of $33.00 per share in a private placement to certain qualified institutional buyers |
Why Ventyx Biosciences Zoomed Nearly 60% Higher This WeekOne standout in a gloomy stock market this week was Ventyx Biosciences (NASDAQ: VTYX). According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's shares soared more than 58% higher during the period, thanks to the approval of a drug that hasn't actually been developed by the company. The treatment in question is Bristol Myers Squibb's deucravacitinib (brand name: Sotyktu), which was approved by the U.S. Food and Drug Administration (FDA) last Friday. |
Bristol Myers Squibb Shakes Up Key Biotech BattlegroundThe FDA approval of Sotyktu for psoriasis has ignited and dampened prospects for smaller biotech stocks. |
VTYX Price Returns
| 1-mo | 71.13% |
| 3-mo | 176.19% |
| 6-mo | 159.55% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 75.78% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...